Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Matrix metalloproteinase-2 activation modulates glioma cell migration.
|
9410885 |
1997 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Delineation of MMP-2 regulation may have implications for development of new therapeutic strategies to arrest glioma invasion.
|
10506168 |
1999 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Quantitative RT-PCR and gelatin zymography showed that gelatinase-A in glioma specimens was higher than in normal tissue; these were significantly elevated in low grade gliomas and remained elevated in GBMs.
|
10206300 |
1999 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
By contrast, the level of TIMP- 1 mRNAs was not altered significantly and that of TIMP-2 was reduced mildly by the HGF/SF treatment, suggesting that HGF/SF may eventually modulate a balance between MMP-2 and TIMPs in favor of the proteinase activity in the glioma cell microenvironment.
|
10389763 |
1999 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Imbalance of TIMP-2/MMP-2 was observed using immunoprecipitation analysis in a glioma cell line.
|
10895974 |
2000 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Rapid activation of matrix metalloproteinase-2 by glioma cells occurs through a posttranslational MT1-MMP-dependent mechanism.
|
10996658 |
2000 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In contrast, enhanced expression of sFRPs inhibits the motility of glioma cells in vitro. sFRP-mediated effects on glioma cells are accompanied by decreased expression and activity of matrix metalloproteinase-2 (MMP-2) and decreased tyrosine phosphorylation of beta-catenin.
|
10980594 |
2000 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Activities of MMP-2 and MMP-9 are the best predictors of glioma cell invasion.
|
11409528 |
2001 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These observations suggest that glioma induces MMP-2 and utilizes its activity in the host tissue to support angiogenesis and to maintain angioarchitecture.
|
12220955 |
2002 |
Glioma
|
0.300 |
Biomarker
|
disease |
LHGDN |
Furthermore, key components (i.e., uPAR, uPA, and pro-MMP-2) were contributed principally by astrocytes, whereas the U251N glioma cells provided plasminogen.
|
12764090 |
2003 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Taken together, our data provide evidence that IGFBP2 contributes to glioma progression in part by enhancing MMP-2 gene transcription and in turn tumor cell invasion.
|
12907597 |
2003 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
These results suggest that up-regulation of Ang2, MMP-2, MT1-MMP, and LN 5 gamma 2 is associated with the invasiveness displayed by human gliomas and that induction of these molecules by Ang2 may be essential for glioma invasion.
|
15743799 |
2005 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Ad5CMV-PTEN transfer into the glioma cell lines lacking the wild-type gene product decreased the levels of matrix metalloproteinase (MMP)-2 mRNA and inhibited the enzymatic activities of MMP-2 and MMP-9.
|
16773187 |
2006 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
The results of RT-PCR showed that the mRNA level of MMP-2 in 9L glioma cells was higher than that of MMP-9, and the mRNA expression of MMP-9 was increased along with the growth of malignant gliomas.
|
17437609 |
2007 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Levels of the proteinase matrix metalloproteinase-2 (MMP-2) are highly increased in gliomas.
|
18438431 |
2008 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Addition of dexamethasone or ectopic expression of wild-type MKP-1 suppressed the SNP-stimulated MMP-2 activation and glioma cell invasiveness in U87MG cells.
|
18652821 |
2008 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Microglial MT1-MMP in turn activates glioma-derived pro-MMP-2 and promotes glioma expansion, as shown in an ex vivo model using MT1-MMP-deficient brain tissue and a microglia depletion paradigm.
|
19617536 |
2009 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we have demonstrated that the RNAi-mediated downregulation of MMP-2 induces apoptosis in the 4910 human glioma xenograft cell line.
|
19724922 |
2009 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In spheroid and Boyden chamber migration assays, inhibition of MMP-2 activity using a specific MMP-2 inhibitor and blocking of integrin alpha(v)beta(3) abrogated glioma cell migration stimulated by TGF-beta2.
|
19033423 |
2009 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Thus, in 3D matrix of CL, MMP-2 expression is modulated by inflammatory cytokines with the concomitant increase in glioma invasiveness.
|
18802741 |
2009 |
Glioma
|
0.300 |
Therapeutic
|
disease |
RGD |
Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression.
|
19292920 |
2009 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Treatment of glioma cell lines with recombinant Nodal (rNodal) increased matrix metalloproteinase 2 (MMP-2) secretion and cell invasiveness.
|
20383200 |
2010 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrate the efficacy of p-MMP-2 in inhibiting radiation-enhanced tumor invasion and progression and suggest that it may act as a potent adjuvant for radiotherapy in glioma patients.
|
21698233 |
2011 |
Glioma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we attempt to investigate the exact molecular mechanism of how MMP-2 depletion leads to apoptosis in glioma xenograft cell lines.
|
21573233 |
2011 |
Glioma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Ionizing radiation activates EGFR signalling and enhances MMP-2 secretion, suggesting that the molecular pathways involved may contribute to the invasiveness and malignant behaviour of glioma cells and help to explain the response of gliomas to ionizing radiation.
|
21289335 |
2011 |